High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. doi:10.1053/j.gastro.2007.04.061
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi:10.3322/canjclin.55.2.74
   PubMed Web of Science ®Google Scholar
• Chedid MF, Kruel CRP, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig. 2017;30(4):272–278. doi:10.1590/0102-6720201700040011
   PubMed Web of Science ®Google Scholar
• Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243–253. doi:10.1007/s11523-017-0484-7
   PubMed Web of Science ®Google Scholar
• Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary Pancreat Dis Int. 2016;15(3):234–256. doi:10.1016/S1499-3872(16)60097-8
   PubMed Web of Science ®Google Scholar
• Tokumitsu Y, Sakamoto K, Tokuhisa Y, et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett. 2018;15(4):4411–4422. doi:10.3892/ol.2018.7821
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li N, Zeng X, et al. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6(6):4440–4450. doi:10.18632/oncotarget.2913
   PubMedGoogle Scholar
• Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a Phase II study. Cancer. 2007;109(7):1384–1390. doi:10.1002/cncr.22532
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem. 2002;238(1–2):163–179. doi:10.1023/A:1019998702946
   PubMed Web of Science ®Google Scholar
• Castiglioni S, Maier JA. Magnesium and cancer: a dangerous liason. Magnes Res. 2011;24(3):S92–S100. doi:10.1684/mrh.2011.0285
   PubMed Web of Science ®Google Scholar
• Schweigel-Röntgen M, Kolisek M. SLC41 transporters–molecular identification and functional role. Curr Top Membr. 2014;73:383–410.
   PubMed Web of Science ®Google Scholar
• Quamme GA. Molecular identification of ancient and modern mammalian magnesium transporters. Am J Physiol Cell Physiol. 2010;298(3):C407–429. doi:10.1152/ajpcell.00124.2009
   PubMed Web of Science ®Google Scholar
• Xie J, Cheng CS, Zhu XY, et al. Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis. Aging (Albany NY). 2019;11(9):2681–2698. doi:10.18632/aging.101940
   PubMedGoogle Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology. 2016;64(5):1818–1819. doi:10.1002/hep.28632
   PubMed Web of Science ®Google Scholar
• Guan L, Luo Q, Liang N, Liu H. A prognostic prediction system for hepatocellular carcinoma based on gene co-expression network. Exp Ther Med. 2019;17(6):4506–4516. doi:10.3892/etm.2019.7494
   PubMed Web of Science ®Google Scholar
• Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. 2016;7:428. doi:10.3389/fphar.2016.00428
   PubMed Web of Science ®Google Scholar
• Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–28. doi:10.1016/j.ctrv.2019.05.004
   PubMed Web of Science ®Google Scholar
• Mandt T, Song Y, Scharenberg AM, Sahni J. SLC41A1 Mg(2+) transport is regulated via Mg(2+)-dependent endosomal recycling through its N-terminal cytoplasmic domain. Biochem J. 2011;439(1):129–139. doi:10.1042/BJ20110807
   PubMedGoogle Scholar
• Sahni J, Nelson B, Scharenberg AM. SLC41A2 encodes a plasma-membrane Mg2+ transporter. Biochem J. 2007;401(2):505–513. doi:10.1042/BJ20060673
   PubMedGoogle Scholar
• Mastrototaro L, Smorodchenko A, Aschenbach JR, Kolisek M, Sponder G. Solute carrier 41A3 encodes for a mitochondrial Mg(2+) efflux system. Sci Rep. 2016;6:27999. doi:10.1038/srep27999
   PubMed Web of Science ®Google Scholar
• Liu J, Lu J, Ma Z, Li W. A nomogram based on a three-gene signature derived from AATF coexpressed genes predicts overall survival of hepatocellular carcinoma patients. Biomed Res Int. 2020;2020:7310768.
   PubMed Web of Science ®Google Scholar
• Freese K, Seitz T, Dietrich P, et al. Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro. Cancers (Basel). 2019;11(10):1587. doi:10.3390/cancers11101587
   PubMed Web of Science ®Google Scholar
• Gong D, Zeng Z, Yi F, Wu J. Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis. Am J Transl Res. 2019;11(2):983–990.
   PubMed Web of Science ®Google Scholar
• Hilvo M, Denkert C, Lehtinen L, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011;71(9):3236–3245. doi:10.1158/0008-5472.CAN-10-3894
   PubMed Web of Science ®Google Scholar
• Hou G, Liu G, Yang Y, et al. Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma. Oncotarget. 2016;7(40):64957–64966. doi:10.18632/oncotarget.11778
   PubMedGoogle Scholar
• Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22(2):823–832. doi:10.3748/wjg.v22.i2.823
   PubMed Web of Science ®Google Scholar
• Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies. Hepatology. 2020. doi:10.1002/hep.31310
   Web of Science ®Google Scholar
• Liu P, Ge M, Hu J, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66(1):167–181. doi:10.1002/hep.29183
   PubMed Web of Science ®Google Scholar
• Dituri F, Mancarella S, Cigliano A, Chieti A, Giannelli G. TGF-β as multifaceted orchestrator in HCC progression: signaling, EMT, immune microenvironment, and novel therapeutic perspectives. Semin Liver Dis. 2019;39(1):53–69. doi:10.1055/s-0038-1676121
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang S, Dai W, Xie C, Li JC. A comprehensive prognostic and immune analysis of SLC41A3 in pan-cancer. Front Oncol. 2021;10:586414. doi:10.3389/fonc.2020.586414
   PubMedGoogle Scholar
• Perugorria MJ, Olaizola P, Labiano I, et al. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121–136. doi:10.1038/s41575-018-0075-9
   PubMed Web of Science ®Google Scholar
• Caja L, Dituri F, Mancarella S, et al. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer. Int J Mol Sci. 2018;19(5):1294. doi:10.3390/ijms19051294
   PubMed Web of Science ®Google Scholar
• Zhang Z, Faouzi M, Huang J, et al. N-Myc-induced up-regulation of TRPM6/TRPM7 channels promotes neuroblastoma cell proliferation. Oncotarget. 2014;5(17):7625–7634. doi:10.18632/oncotarget.2283
   PubMedGoogle Scholar
• Mishra R, Rao V, Ta R, Shobeiri N, Hill CE. Mg2+- and MgATP-inhibited and Ca2+/calmodulin-sensitive TRPM7-like current in hepatoma and hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2009;297(4):G687–694. doi:10.1152/ajpgi.90683.2008
   PubMed Web of Science ®Google Scholar
• Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg2+-sensitive Socs3a signaling in development and cancer. Dis Model Mech. 2011;4(2):240–254. doi:10.1242/dmm.004564
   PubMed Web of Science ®Google Scholar
• Gao SL, Kong CZ, Zhang Z, Li ZL, Bi JB, Liu XK. TRPM7 is overexpressed in bladder cancer and promotes proliferation, migration, invasion and tumor growth. Oncol Rep. 2017;38(4):1967–1976. doi:10.3892/or.2017.5883
   PubMed Web of Science ®Google Scholar
• Sasahira T, Nishiguchi Y, Kurihara-Shimomura M, Nakashima C, Kuniyasu H, Kirita T. NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2018;144(5):875–882. doi:10.1007/s00432-018-2612-x
   PubMed Web of Science ®Google Scholar